Literature DB >> 707543

Fatal pulmonary hypertension and resolving immune-complex glomerulonephritis in mixed connective tissue disease. A case report and review of the literature.

M B Jones, R K Osterholm, R B Wilson, F H Martin, J R Commers, J D Bachmayer.   

Abstract

Mixed connective tissue disease (MCTD) has been characterized as a benign rheumatic syndrome with a favorable response to immunosuppressive therapy. Serious renal and pulmonary involvement are reported to be rare in MCTD. We are describing a female adolescent with MCTD in whom fatal cor pulmonale developed due to recurrent thromboembolic primary pulmonary hypertension. Death occurred after two years of therapy with prednisone and azathioprine for an immune-complex glomerulonephritis. Paramesangial and intramembranous electron-dense deposits had been identified in several glomeruli at the start of treatment. Improved renal function and apparent histologic improvement were demonstrated four months after the institution of prednisone and azathioprine therapy, and stable renal function was maintained until death. The pulmonary hypertension was progressive and apparently not altered by either the prednisone or azathioprine. At necropsy, there was no evidence of a pulmonary arteritis or vascular immune-complex deposition to account for the recurrent thromboembolic lesions in the small pulmonary arteries and arterioles. This is a clinical course not previously described in patients with MCTD and may represent an extreme of the clinical spectrum of this syndrome.

Entities:  

Mesh:

Year:  1978        PMID: 707543     DOI: 10.1016/0002-9343(78)90806-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

1.  Recovery from pulmonary hypertension in an adolescent with mixed connective tissue disease.

Authors:  D M Friedman; H J Mitnick; D Danilowicz
Journal:  Ann Rheum Dis       Date:  1992-08       Impact factor: 19.103

2.  Pulmonary hypertension in connective tissue disease. Clinical analysis of sixty patients in multi-institutional study.

Authors:  R Kasukawa; T Nishimaki; T Takagi; S Miyawaki; R Yokohari; T Tsunematsu
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

3.  Pulmonary hypertension in connective tissue disease.

Authors:  M Demedts
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

4.  Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost.

Authors:  Judit Végh; Györgyike Soós; István Csipõ; Nóra Demeter; Thomas Ben; Balázs Dezsõ; Margit Zeher; Katalin Dévényi; János Gaál; Gyula Szegedi; Edit Bodolay
Journal:  Rheumatol Int       Date:  2005-07-12       Impact factor: 2.631

5.  Circulating lupus type anticoagulant and pulmonary hypertension associated with mixed connective tissue disease.

Authors:  P Hainaut; E Lavenne; J M Magy; E G Lebacq
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

6.  Pulmonary hypertension in MCTD: report of two cases with anticardiolipin antibody.

Authors:  M Miyata; S Kida; T Kanno; K Suzuki; H Watanabe; S Kaise; T Nishimaki; Y Hosoda; R Kasukawa
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

7.  Cellular regulation of anti-nRNP antibody synthesis is different from that of anti-DNA antibody synthesis in patients with systemic lupus erythematosus.

Authors:  O Hosono; T Takeuchi; J Koide; M Takano; T Abe
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

8.  Mixed connective tissue disease with fatal pulmonary hypertension and a review of literature.

Authors:  N Ueda; K Mimura; H Maeda; T Sugiyama; T Kado; K Kobayashi; H Fukuzaki
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

9.  Clinical profiles of patients with antibodies to nuclear ribonucleoprotein.

Authors:  J Calderon; V Rodriguez-Valverde; S Sanchez Andrade; J L Riestra; J Gomez-Reyno
Journal:  Clin Rheumatol       Date:  1984-12       Impact factor: 2.980

10.  Is MCTD a distinct entity? Comparison of clinical and laboratory findings in MCTD, SLE, PSS, and RA patients.

Authors:  L S De Clerck; K A Meijers; A Cats
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.